Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC

• Kim Monkhorst,
• Daniel Klass,
• Milou Schuurbiers,
• Zhongyun Huang,
• Senglor Saelee,
• Manana Javey,
• Leonie de Visser,
• Daan van den Broek,
• Michel van den Heuvel,
• Alexander F Lovejoy

Affiliations

Kim Monkhorst

Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

Daniel Klass

1Stanford Cancer Institute and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA

Milou Schuurbiers

Department of Pulmonology, Radboud university medical center - Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands

Zhongyun Huang

Roche Sequencing Solutions, Pleasanton, California, USA

Senglor Saelee

Roche Sequencing Solutions, Pleasanton, California, USA

Manana Javey

Roche Sequencing Solutions, Pleasanton, California, USA

Leonie de Visser

Roche Diagnostics International AG, Rotkreuz, Zug, Switzerland

Daan van den Broek

Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands

Michel van den Heuvel

Department of Pulmonology, Radboud university medical center - Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands

Alexander F Lovejoy

Roche Sequencing Solutions, Pleasanton, California, USA